Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

(2014) K. Beldjord et al.   BLOOD

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

(2014) Anjali S. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab

(2014) P. Schlegel et al.   HAEMATOLOGICA

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

(2014) Lindsey M. Hoffman et al.   Frontiers in Oncology

Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission

(2013) Jessica Hochberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

(2013) H. Carol et al.   CLINICAL CANCER RESEARCH

BCR-ABL1 molecular remission after90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+Ph+B-ALL: proof of principle

(2013) Patrice Chevallier et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: A case report

(2013) Ramy Rahmé et al.   EXPERIMENTAL HEMATOLOGY

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia

(2013) Matthew J Barth et al.   Future Oncology

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

(2013) M Le Garff-Tavernier et al.   LEUKEMIA

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen

(2012) Maria Liga et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia

(2012) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia

(2012) Stefan K. Barta et al.   LEUKEMIA & LYMPHOMA

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation

(2011) Koen van Besien et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

(2011) E. Doubrovina et al.   BLOOD

Chemoimmunotherapy in acute lymphoblastic leukemia

(2011) Dieter Hoelzer et al.   BLOOD REVIEWS

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

(2011) John Schindler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

(2011) D. J. FitzGerald et al.   CANCER RESEARCH

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

(2011) V. Blanc et al.   CLINICAL CANCER RESEARCH

Cellular Therapies in Acute Lymphoblastic Leukemia

(2011) Jae H. Park et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Modern Therapy of Acute Lymphoblastic Leukemia

(2011) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

(2011) Sara Raponi et al.   LEUKEMIA & LYMPHOMA

Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia

(2011) D. Hoelzer   Hematology-American Society of Hematology Education Program

Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing

(2010) Elaine Coustan-Smith et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

(2010) Jorge E. Romaguera et al.   BRITISH JOURNAL OF HAEMATOLOGY

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma

(2010) G. O. Negrea et al.   HAEMATOLOGICA

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma

(2010) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

(2010) Pier Paolo Piccaluga et al.   LEUKEMIA & LYMPHOMA

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

(2009) S. Maury et al.   HAEMATOLOGICA

Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia

(2009) Deborah A. Thomas et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia

(2009) Larry Herrera et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

(2009) Claudia Stolz et al.   LEUKEMIA & LYMPHOMA

The late adverse events of rituximab therapy – rare but there!

(2009) Ron Ram et al.   LEUKEMIA & LYMPHOMA

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

(2009) Anne L. Angiolillo et al.   PEDIATRIC BLOOD & CANCER

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

(2008) M. N. Dworzak et al.   BLOOD

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

(2008) D. A. Thomas et al.   BLOOD

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

(2008) Jerzy Holowiecki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling

(2008) Claire A. Walshe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE